WellPoint’s research subsidiary, HealthCore, is partnering with AstraZeneca to analyze claims, medical records and other real-world evidence to identify effective, affordable ways to treat disease. By examining data associated with care delivery, real-world analyses can assess the impact of medical treatments on key health outcomes such as readmissions and overall cost of care.
The collaboration works with private and public organizations, including state Medicaid programs, to determine how benefit design, health policies, practice patterns and geographic and demographic variations can impact the total value of care delivery.
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.